Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan:75:103780.
doi: 10.1016/j.ebiom.2021.103780. Epub 2021 Dec 23.

Clinical tools and biomarkers to predict preeclampsia

Teresa M MacDonald  1 , Susan P Walker  1 , Natalie J Hannan  2 , Stephen Tong  2 , Tu'uhevaha J Kaitu'u-Lino  3
Affiliations
Review

Clinical tools and biomarkers to predict preeclampsia

Teresa M MacDonald et al. EBioMedicine. 2022 Jan.

Abstract

Preeclampsia is pregnancy-specific, and significantly contributes to maternal, and perinatal morbidity and mortality worldwide. An effective predictive test for preeclampsia would facilitate early diagnosis, targeted surveillance and timely delivery; however limited options currently exist. A first-trimester screening algorithm has been developed and validated to predict preterm preeclampsia, with poor utility for term disease, where the greatest burden lies. Biomarkers such as sFlt-1 and placental growth factor are also now being used clinically in cases of suspected preterm preeclampsia; their high negative predictive value enables confident exclusion of disease in women with normal results, but sensitivity is modest. There has been a concerted effort to identify potential novel biomarkers that might improve prediction. These largely originate from organs involved in preeclampsia's pathogenesis, including placental, cardiovascular and urinary biomarkers. This review outlines the clinical imperative for an effective test and those already in use and summarises current preeclampsia biomarker research.

Keywords: Biomarkers; Placenta; Prediction; Preeclampsia.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest TKL, TM, SW and ST hold a provisional patent (PCT/AU2019/050516) relating to the use of SPINT1 and syndecan-1 as diagnostic markers for placental insufficiency. The remaining authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Schematic outlining the potential sources of biomarkers for preeclampsia and types that may be measured. Preeclampsia is associated with placental insufficiency that leads to significant endothelial dysfunction and organ involvement. As such, the placenta and endothelial cells represent potential sources of potential biomarkers that may be in the form of RNAs, DNA, metabolites proteins.
See this image and copyright information in PMC

References

    1. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet. 2021 London, England. - PubMed
    1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–e333. - PubMed
    1. Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2018;218(3):287–293. e1. - PubMed
    1. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017;377(7):613–622. - PubMed
    1. Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet. 1985;1(8433):840–842. - PubMed

Substances